Previous 10 | Next 10 |
home / stock / wuxif / wuxif news
2023-12-06 02:05:56 ET Summary WuXi Biologics is a contract-based drug developer in China, but recent share price performance has lagged. The company is expecting a major miss in revenues for FY 2023 due mostly to over-optimism, causing a 30% decline in share price. Despite th...
2023-03-27 23:00:00 ET Summary Wuxi AppTec’s chemical business doubled last year, but only grew around 40% excluding revenue from Covid-related products and services. The drug outsourcing services company’s net profit fell 47.6% sequentially to 1.44 billion yuan in t...
Summary China pharma company Jinxi Jemincare out-licensed global rights for its androgen receptor degrader to Roche in a $650 million agreement. The oral small-molecule candidate, developed in Jemincare’s R&D center, is currently in preclinical testing. Shanghai IASO Bi...
Summary Beijing BoomRay Pharma, a joint venture between WuXi AppTec and Peking University, completed a $43 million Series A funding to develop novel radionuclide drugs that integrate diagnosis and treatment. Nanjing Frontier Biotechnologies completed a $29 million private placemen...
Frontera Therapeutics completed a $160 million Series B funding to support its AAV programs. Merck KGaA announced its Uptune program will back Asia startup companies with up to €100,000 each to advance their projects into proof-of-concept studies. Shanghai Antengene will co...
Pfizer ( NYSE: PFE ) backed Chinese cancer drugmaker CStone Pharmaceuticals ( OTCPK:CSPHF ) is exploring strategic options, including a sale of the company, Bloomberg News reported citing people with knowledge of the matter. WuXi Healthcare Ventures, a unit of...
Harding Loevner has been investing globally in high-quality, growing businesses based on disciplined industry research since 1989. Emerging Markets (EMs) declined sharply, primarily due to the collapse in Russian equities brought about by economic sanctions against Russia because of i...
Wuhan Binhui Biopharm closed a $47 million Series B financing to support its R&D of oncolytic virus products. Amoy Diagnostics, a Shanghai novel molecular diagnostics company, signed a collaboration agreement to develop companion diagnostics for AstraZeneca drugs. Hangzhou Asc...
The CXO giant announced it expects to post record-high revenue in the first quarter of 2022. WuXi AppTec said it expects year-on-year revenue growth of 65% to 68% in the first quarter of this year. The provider of drug development services is ranked relatively weaker than its peer...
Concord, Mass.-based Adiso Therapeutics, an anti-inflammatory biotech, officially emerged from stealth mode with backing from Hong Kong's Morningside Ventures. Morningside has already invested $60 million in the company and has another $35 million earmarked for the company's B round. ...